The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call
AbbVie’s second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable gains in the neuroscience portfolio. CEO Robert Michael emphasized that “each [portfolio] delivered growth above 20%,” with SKYRIZI achieving market leadership in multiple countries. However, the quarter also saw persistent biosimilar pressure on legacy products and a competitive landscape in key markets.
Is now the time to buy ABBV? Find out in our full research report (it’s free for active Edge members).
AbbVie (ABBV) Q2 CY2026 Highlights:
- Revenue: $16.99 billion vs analyst estimates of $16.79 billion (10.2% year-on-year growth, 1.2% beat)
- Adjusted EPS: $3.65 vs analyst estimates of $3.61 (1.2% beat)
- Management lowered its full-year Adjusted EPS guidance to $13.97 at the midpoint, a 1.5% decrease
- Operating Margin: 37.9%, up from 31.7% in the same quarter last year
- Market Capitalization: $430.9 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From AbbVie’s Q2 Earnings Call
- Terence Flynn (Morgan Stanley) asked about SKYRIZI’s subcutaneous induction approval timeline and manufacturing readiness. EVP Roopal Thakkar assured that the “review is going according to plan” and no manufacturing issues have emerged.
- Carter Lewis Gould (Cantor Fitzgerald) questioned the strategy for large-scale IBD trials and whether interim data could accelerate phase 3 initiation. Thakkar explained the intent to move rapidly into phase 3 based on promising interim results from the ongoing combination studies.
- Christopher Schott (JPMorgan) pressed on SKYRIZI’s growth prospects in psoriasis amid new competition. EVP Jeffrey Stewart stated that SKYRIZI’s momentum remains robust, with new patient starts actually increasing since competitor launches.
- Michael Yee (UBS) inquired about expectations for the Tevapadon launch in Parkinson’s disease and differentiation of AbbVie’s brain shuttle technology. Stewart predicted a modest initial ramp for Tevapadon due to formulary timing, while Thakkar described the brain shuttle as enabling higher drug penetration and improved patient convenience.
- Mohit Bansal (Wells Fargo) asked for evidence supporting lutikizumab’s efficacy in hidradenitis suppurativa and the handling of GLP-1 use in trials. Thakkar pointed to strong phase 2 data and large trial sizes to account for GLP-1 effects, noting a dual strategy with RINVOQ and lutikizumab.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will monitor (1) the outcome of regulatory reviews for SKYRIZI’s subcutaneous induction and new dermatology indications for RINVOQ, (2) the commercial launch progress of Tevapadon in Parkinson’s disease and Bowie in aesthetics, and (3) the integration of Apogee Therapeutics and the impact of new immunology assets. Progress in the oncology pipeline and margin management will also be key indicators.
AbbVie currently trades at $243.95, down from $257.41 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.